on DocMorris AG (isin : CH0042615283)
DocMorris Reports Significant eRx Growth in Q2 2024
In its latest quarterly update, DocMorris AG reveals substantial growth in new e-prescription (eRx) customers and revenue. The introduction of the "CardLink" redemption channel has tripled new Rx customers and doubled market share since January 2024.
DocMorris' external revenue in Q2 2024 grew by 6.4% in local currency, reaching CHF 267.7 million. The number of active customers increased by 300,000, totaling 10 million by June 2024.
In Germany, e-prescription revenue increased by over 50%, despite a decline in paper prescription revenues. Overall Rx revenue in local currency rose by 17% compared to the previous quarter. Over-the-counter (OTC) medicine sales grew by 7.9%.
In Spain and France, DocMorris also saw a turnaround with 3.2% revenue growth in local currency. The company maintains its revenue and EBITDA outlook, with more detailed results to be shared in August.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DocMorris AG news